BLA 761137 · Astellas
Padcev
Enfortumab Vedotin-Ejfv · Injection
NovelBreakthrough therapyAccelerated approvalPriority reviewLast checked: Nov 20, 2026Latest source record: Jul 10, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Dec 18, 2019
Approved uses
8
Original approval plus efficacy supplements
Registered trials
90
13 Phase 3, 49 recruiting
FAERS reports
7,851
6,925 serious, 1,561 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS SKIN REACTIONS • PADCEV can cause severe and fatal cutaneous adverse reactions including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), which occurred predominantly during the first cycle of treatment, but may occur later. • Closely monitor patients for skin reactions. • Immediately withhold PADCEV and consider referral for specialized care for suspected SJS or TEN or severe skin reactions. • Permanently discontinue PADCEV in patients with confirmed SJS or TEN; or Grade 4 or recurrent Grade 3 skin reactions [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.1 ), and Adverse Reactions ( 6.1 )]. WARNING: SERIOUS SKIN REACTIONS See full prescribing information for complete boxed warning. • PADCEV can cause severe and fatal cutaneous adverse reactions, including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). •...
What it is approved for
From the label in effect Aug 4, 2026.
PADCEV ® , in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment, is indicated for the treatment of adult patients with muscle invasive bladder cancer (MIBC). PADCEV ® , in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer (la/mUC). PADCEV, as a single agent, is indicated for the treatment of adult patients with la/mUC who: • have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and platinum-containing chemotherapy, or • are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy. PADCEV is a Nectin-4-directed antibody and microtubule inhibitor conjugate indicated: • in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment, for the treatment of adult patients with muscle invasive bladder cancer (MIBC). ( 1 ) • in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, for the treatment of adult patients with locally advanced or metastatic urothelial cancer (la/mUC). ( 1 ) • as a single agent for the treatment of adult patients with la/mUC who: ○ have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and platinum-containing chemotherapy, or ○ are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy. ( 1 )
Mechanism: Enfortumab vedotin-ejfv is an ADC. The antibody is a human IgG1 kappa directed against Nectin-4, an adhesion protein located on the surface of cells. The small molecule, MMAE, is a microtubule-disrupting agent, attached to the antibody via a protease-cleavable linker. Nonclinical data suggest that the anticancer activity of enfortumab vedotin-ejfv is due to the binding of the ADC to Nectin-4-expressing cells, followed by internalization of the ADC-Nectin-4 complex, and the release of MMAE via proteolytic cleavage. Release of MMAE disrupts the microtubule network within the cell, subsequently...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 10, 2026 Supplement 37 · Efficacy · priority review LetterLabel
- Nov 21, 2025 Supplement 32 · Efficacy · priority review LetterLabel
- Dec 15, 2023 Supplement 24 · Efficacy · priority review LabelLetter
- Dec 15, 2023 Supplement 25 · Efficacy · priority review LabelLetter
- Apr 3, 2023 Supplement 18 · Efficacy · priority review Breakthrough therapyPatient Information SheetLetter
- Jul 9, 2021 Supplement 8 · Efficacy · priority review LabelLetter
- Jul 9, 2021 Supplement 6 · Efficacy · priority review LabelLetter
- Dec 18, 2019 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalLabelLetterReview
2 products under this application
- PADCEV · ENFORTUMAB VEDOTIN-EJFV 20MG/VIAL · INJECTABLE, INJECTION · Prescription
- PADCEV · ENFORTUMAB VEDOTIN-EJFV 30MG/VIAL · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Enfortumab Vedotin" as an intervention, any sponsor and status, largest first.
- An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUCPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07720284 · 915 participants (planned) · Start Jul 16, 2026 · Primary completion Sep 11, 2030
Drug: Dato-DXd; Rilvegostomig and 4 more · For: High-risk Muscle Invasive Urothelial Carcinoma
Sites: Hot Springs, Arkansas; Little Rock, Arkansas; San Francisco, California · 160 sites in all
- Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial CancerPivotal-lookingActive, not recruiting
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT04223856 · 886 participants · Start Mar 30, 2020 · Primary completion Aug 8, 2023
Drug: Enfortumab vedotin; Pembrolizumab and 3 more · For: Urothelial Cancer
Sites: Chandler, Arizona; Tucson, Arizona; Burbank, California · 260 sites in all
- Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04700124 · 808 participants · Start Apr 21, 2021 · Primary completion Oct 27, 2025
Drug: Pembrolizumab; Enfortumab vedotin (EV) and 2 more · For: Bladder Cancer
Sites: Phoenix, Arizona; Fullerton, California; Los Angeles, California · 188 sites in all
- A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial CarcinomaPivotal-lookingRecruiting
Summit TherapeuticsIndustry
NCT07815665 · 800 participants (planned) · Start Sep 10, 2026 · Primary completion Oct 31, 2030
Drug: Ivonescimab Dose 1; enfortumab vedotin (EV) and 3 more · For: Metastatic Urothelial Carcinoma; Metastatic Urothelial Carcinoma (UC)
Sites: Phoenix, Arizona; Los Angeles, California; Washington D.C., District of Columbia · 7 sites in all
- Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse CisplatinPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT04960709 · 712 participants · Start Aug 5, 2021 · Primary completion Mar 2, 2026
Drug: Durvalumab; Tremelimumab and 1 more · For: Muscle Invasive Bladder Cancer
Sites: Orange, California; Santa Monica, California; New Haven, Connecticut · 196 sites in all
- Modular Trial of sEphB4-HSA in EphrinB2-High Solid TumorsPivotal-lookingRecruiting
Vasgene Therapeutics, IncIndustry
NCT06493552 · 700 participants (planned) · Start Mar 15, 2025 · Primary completion Sep 2029
Drug: SEphB4-HSA; Pembrolizumab and 3 more · For: Muscle-Invasive Bladder Carcinoma; Metastatic Urothelial Carcinoma
Sites: Santa Monica, California
Eli Lilly and CompanyEli Lilly (LLY)
NCT05614739 · 677 participants (planned) · Start Jan 12, 2023 · Primary completion Jun 2027
Drug: Vepugratinib; Pembrolizumab and 5 more · For: Urinary Bladder Neoplasms; Neoplasm Metastasis; Ureteral Neoplasms
Sites: Tucson, Arizona; Duarte, California; Los Angeles, California · 83 sites in all
- Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial CarcinomaPivotal-lookingRecruiting
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT07129993 · 630 participants (planned) · Start Sep 26, 2025 · Primary completion Jun 1, 2029
Drug: Dato-DXd; Carboplatin and 2 more · For: Urothelial Cancer; Bladder Cancer
Sites: Fullerton, California; Glendale, California; La Jolla, California · 100 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- rash1,019
- neuropathy peripheral909
- malignant neoplasm progression893
- diarrhoea503
- pruritus467
- death436
- decreased appetite424
- fatigue423
- off label use362
- alopecia324
- skin disorder314
- pyrexia313
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2017 | 2 |
| 2018 | 1 |
| 2020 | 221 |
| 2021 | 328 |
| 2022 | 877 |
| 2023 | 951 |
| 2024 | 1,165 |
| 2025 | 2,438 |
| 2026 | 1,868 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Padcev (Enfortumab Vedotin-Ejfv)
2024 spending
$9.4M
Beneficiaries
75
381 claims
Per beneficiary
$125,841
$3,616.71 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,572,893 |
| 2021 | $1,634,736 |
| 2022 | $2,790,214 |
| 2023 | $4,437,952 |
| 2024 | $9,438,058 |
Part B: Padcev (Enfortumab Vedotin-Ejfv) · HCPCS J9177
2024 spending
$641M
Beneficiaries
5,839
50,610 claims
Per beneficiary
$109,818
2024 ASP limit $36.02 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $63,345,400 |
| 2021 | $154,355,577 |
| 2022 | $189,323,880 |
| 2023 | $311,587,696 |
| 2024 | $641,224,462 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
Powles T, Valderrama BP, Gupta S, et al. · N Engl J Med 2024 · Clinical Trial, Phase III, Comparative Study
- Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer.
Vulsteke C, Adra N, Danchaivijitr P, et al. · N Engl J Med 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.
Powles T, Rosenberg JE, Sonpavde GP, et al. · N Engl J Med 2021 · Clinical Trial, Phase III, Comparative Study
- Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302/KEYNOTE-A39 trial.
Powles TB, Van der Heijden MS, Loriot Y, et al. · Ann Oncol 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
- Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer.
Galsky MD, Valderrama BP, Maruzzo M, et al. · N Engl J Med 2026 · Clinical Trial, Phase III, Comparative Study
- Enfortumab Vedotin With or Without Pembrolizumab in Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
Yajima S, Hirose K, Masuda H · JAMA Netw Open 2025 · Systematic Review, Network Meta-Analysis
Sponsor: Astellas
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.